Weighted Blanket to Improve Sedation and Comfort During Ventilator Weaning
A Randomized Controlled Trial of a Hospital-Grade Weighted Blanket to Improve Sedation Quality During Ventilator Weaning in the Blake 7 MICU (MGH)
Patients in the ICU who are being taken off of a breathing machine (ventilator weaning) commonly experience anxiety, agitation, sleep disruption, and physiologic stress. Weighted blankets have been used to improve patient comfort; however, the design of standard weighted blankets can interfere with the ICU environment and are often not adaptable to individual patient needs. This study will evaluate a weighted blanket specifically designed for ICU use, with features that allow adjustable weight and flexible configuration (e. g., full body, shoulder, or lap).
This study aims to determine whether the ICU-adapted weighted blanket:
- Improves sedation quality, measured using the Richmond Agitation-Sedation Scale (RASS), which is already part of routine ICU care
- Helps patients stay in a light, comfortable level of sedation during ventilator weaning
- Is safe, feasible, and acceptable for use in the ICU environment
Participants will be randomly assigned (like flipping a coin) to one of two groups:
- Weighted blanket group, or
- Standard linen group
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
To help manage symptoms and discomfort while patients are being taken off of a breathing machine (ventilator weaning), patients are often treated with sedative medications to keep them calm or sleepy. While these medications are often necessary, they can sometimes lead to problems such as needing the breathing machine for longer, confusion (delirium), poor sleep, and longer stays in the ICU. Current ICU practice aims to use lighter levels of sedation when possible. As sedation is reduced, there is a need for safe, low-risk, non-medication approaches that help keep patients comfortable without affecting their alertness or breathing.
Previous studies suggest that weighted blankets may reduce anxiety and physiologic stress without negatively affecting vital signs. However, the standard design of commercially available weighted blankets can affect their safety and usability. These include materials and construction that are not ideal for hospital use, excessive heat retention, special washing requirements, limited ability to adjust blanket weight, and interference with medical lines, tubes, and equipment.
These observations, along with clinician feedback, informed the development of a hospital-grade weighted blanket designed specifically for ICU use. This weighted blanket allows the amount of weight to be adjusted (5-20 pounds) and can be applied in different ways (e. g., over the full body, on the shoulders, or on the lap) depending on patient needs. It is designed to work safely alongside standard hospital equipment and fits within routine ICU care.
This study will compare the use of this weighted blanket to standard hospital linens to understand whether this weighted blanket improves patient comfort. This study is a randomized controlled trial in which participants are randomly assigned to receive either (1) the weighted blanket or (2) standard hospital linens. The study will enroll 64 patients. Participants will remain in the study until removal of mechanical ventilation (extubation). All data collected are part of routine care, and patient care will not be altered by study participation.
The trial will take place at the Blake 7 Medical Intensive Care Unit at Massachusetts General Hospital.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Age ≥18 years
- Intubated and mechanically ventilated
- Receiving sedation and/or analgesia
- Documented clinical decision to initiate ventilator weaning
- Patient or legally authorized representative (LAR)/healthcare proxy (HCP) able to provide informed consent
Exclusion Criteria:
- Conditions in which deep pressure / blanket application may compromise safety in the opinion of the treating clinical team
- Braden Scale score ≤9 with evidence of significant skin compromise
- Patients with pre-existing pressure injuries on posterior, weight-bearing body surfaces (e.g., sacrum, coccyx, heels) will be excluded
- Recent major surgery or unstable fractures affecting the torso
- Continuous prone positioning
- Body mass index ≥35 kg/m² as a precautionary exclusion due to uncertainty regarding pressure distribution and respiratory mechanics during early feasibility testing
- Concurrent enrollment in another interventional trial affecting sedation or ventilation
- Anticipated withdrawal of life-sustaining therapy
- Pregnant individuals in the 2nd or 3rd trimester
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Podpůrná péče
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Weighted blanket
The intervention group will receive the hospital-grade weighted blanket, to add on to usual care.
|
For participants in the weighted blanket group:
|
|
Falešný srovnávač: Standard hospital linens
The control group will receive standard hospital bedding, which is part of usual care.
|
For participants in the standard hospital linens group:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Sedation quality
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Sedation and agitation will be measured using the Richmond Agitation-Sedation Scale (RASS). This scale ranges from +4 (combative) to -5 (unarousable), with 0 indicating an alert and calm state. Positive scores reflect agitation and negative scores reflect increasing levels of sedation. Sedation quality is defined as the proportion of time patients spend within a goal RASS score, between 0 to +1, during ventilator weaning. This range reflects intended light sedation during ventilator weaning to preserve alertness and respiratory drive. |
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Acceptability of study
Časové okno: From initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Acceptability will be defined as less than or equal to 33% blanket rejection rate by patients.
Blanket rejection will consist of patient or clinician request for the blanket to be permanently removed.
|
From initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Sedative and analgesic exposure
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Measured total amount of sedation and analgesia received from time weaning initiated to extubation, normalized per weight and time on study.
Dose and frequency data will be derived from routine clinical documentation in the Epic Medication Administration Record (EPIC MAR).
|
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Time to extubation
Časové okno: From initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
The time between ventilator weaning and extubation will be derived from Epic nursing flowsheets.
|
From initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Delirium incidence
Časové okno: Daily from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Delirium will be assessed when RASS scores range between -1 to +1, using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).
The CAM-ICU evaluates acute onset or fluctuating mental status, inattention, altered level of consciousness, and disorganized thinking.
Delirium will be defined as present when features 1 and 2, plus either feature 3 or 4, are positive.
Delirium incidence will be recorded as a binary outcome (present/absent) during the study period.
|
Daily from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Pain severity
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Pain will be assessed using the Critical-Care Pain Observation Tool (CPOT) in patients unable to self-report.
The tool includes four domains: facial expression, body movements, muscle tension, and compliance with the ventilator (or vocalization in non-intubated patients), each scored from 0 to 2 (total score 0-8).
A CPOT score ≥3 will be considered indicative of clinically significant pain.
|
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Anxiety scores
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Anxiety/agitation level will be assessed using the Richmond Agitation-Sedation Scale (RASS).
The RASS ranges from +4 (combative) to -5 (unarousable), with 0 indicating an alert and calm state.
Positive scores reflect agitation and negative scores reflect increasing levels of sedation.
|
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
ICU length of stay
Časové okno: From ICU admission until ICU discharge, assessed for up to one month.
|
The time between admission to the ICU and discharge from the ICU will be measured.
This information will be derived from discharge documentation in Epic.
|
From ICU admission until ICU discharge, assessed for up to one month.
|
|
Incidence of new Grade 2 or higher pressure injury
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Safety event defined as development of a new Grade 2 or higher pressure injury.
Pressure injury will be measured using the Braden Scale and by visual skin inspection.
Risk factors are divided into six categories and are rated on a scale of 1 to 4. These measures are added up, and the total score indicates a patient's risk level for developing a pressure injury.
A range between 19-23 indicates no risk, 15-18 indicates mild risk, 13-14 is a moderate risk, 10-12 is a high risk, and any number less than 9 is a severe risk.
|
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Incidence of sustained elevated core temperature
Časové okno: Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
Safety event defined as a core temperature greater than 100.4 degrees Fahrenheit (38 degrees Celsius) that persists of greater than or equal to 1 hour after blanket removal without alternative clinical explanation.
Core temperature will be measured with standard Medical ICU temperature monitoring.
|
Every 4 hours from initiation of ventilator weaning until extubation, assessed for up to two weeks.
|
|
Feasibility success
Časové okno: From study initiation until the last participant completes study participation, assessed for up to 1 year.
|
Feasibility success will be defined as achievement of both prespecified feasibility criteria: (1) enrollment of ≥50% of eligible participants and (2) collection of complete outcome data for ≥80% of enrolled participants.
The outcome will be reported as whether the study met both feasibility criteria.
|
From study initiation until the last participant completes study participation, assessed for up to 1 year.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Jennifer E. Cahill, PhD, RN, Massachusetts General Hospital
Publikace a užitečné odkazy
Obecné publikace
- Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-e873. doi: 10.1097/CCM.0000000000003299.
- Mullen B, Champagne T, Krishnamurty S, Dickson D, Gao RX. Exploring the safety and therapeutic effects of deep pressure stimulation using a weighted blanket. Am J Occup Ther. 2008;62(1):65-72.
- Eron K, Kohnert L, Watters A, Logan C, Weisner-Rose M, Mehler PS. Weighted Blanket Use: A Systematic Review. Am J Occup Ther. 2020 Mar/Apr;74(2):7402205010p1-7402205010p14. doi: 10.5014/ajot.2020.037358.
- Olsen HT, Nedergaard HK, Strom T, Oxlund J, Wian KA, Ytrebo LM, Kroken BA, Chew M, Korkmaz S, Lauridsen JT, Toft P. Nonsedation or Light Sedation in Critically Ill, Mechanically Ventilated Patients. N Engl J Med. 2020 Mar 19;382(12):1103-1111. doi: 10.1056/NEJMoa1906759. Epub 2020 Feb 16.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- 2026P000726
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .